Providers should consider COVID-19 antibody testing for patients in certain circumstances, such as for patients with acute respiratory tract disease as a complement to NAAT, especially in patients in whom COVID-19 disease is suspected and NAAT results are negative, and in patients with resolved serious upper respiratory tract infection that occurred during the pandemic. Additionally, antibody should not be used as an indication of resolved infection or protection from future infection. Further, providers should fully inform patients of issues associated with testing (e.g. false negative/positives) and perform tests using assays from reputable companies.
- COVID-19 Frequently Asked Questions
- Chloroquine or hydroxychloroquine not recommended for treatment of COVID-19
- Recommendations for Long-Term Care Facilities related to Facility Transfers and Care Coordination for COVID-19 Positive (and Negative) Residents
- Review of Current SARS-CoV-2 Test Methods and Recommendations for Increasing Testing Capacity in New Mexico
- Use of ivermectin in the treatment of COVID-19